Table 1.
Patient and treatment characteristics
| Variable | Strata | Study group |
|---|---|---|
| N | 907 | |
| Age | <21 | 220 (24.3%) |
| ≥21 | 687 (75.7%) | |
| Age (y) | Median (range) | 43.8 (1-75) |
| Patient gender | Male | 536 (59.1%) |
| Female | 371 (40.9%) | |
| Gender match | Match | 366 (40.4%) |
| Mismatch | 541 (59.6%) | |
| Diagnosis | ALL | 219 (24.1%) |
| AML | 356 (39.3%) | |
| MDS/MPN/CML | 181 (20.0%) | |
| NHL/Hodgkin/CLL | 106 (11.7%) | |
| Other malignancy | 45 (5.0%) | |
| Diagnosis risk | High risk | 317 (35.0%) |
| Prior autologous HCT | Yes | 53 (5.8%) |
| CMV serostatus | Positive | 519 (57.2%) |
| Conditioning | MA | 494 (54.5%) |
| RIC | 413 (45.5%) | |
| GVHD prophylaxis | Csa or Tac with MTX | 263 (29.0%) |
| Csa or Tac with MMF | 623 (68.7%) | |
| Other | 21 (2.3%) | |
| Donor type | Matched sibling | 322 (35.5%) |
| Matched URD | 73 (8.0%) | |
| Single UCB | 135 (14.9%) | |
| Double UCB | 377 (41.6%) | |
| Stem cell source | Marrow MSD | 53 (5.8%) |
| PBSC MSD | 269 (29.7%) | |
| Marrow URD | 62 (6.8%) | |
| PBSC URD | 11 (1.2%) | |
| UCB | 512 (56.4%) | |
| Year of HCT | 2000-2007 | 558 (61.5%) |
| 2008-2012 | 349 (38.5%) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; CML, chromic myeloid leukemia; CMV, cytomegalovirus; MA, myeloablative conditioning; MDS, myelodysplastic syndrome; MMF, mycophenolate mofetil; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma.